Cadence Capital Management’s Anika Therapeutics ANIK Stock Holding History

Cadence Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-25,289	Closed	-$1.24M	–	667
2016 Q4	$1.24M	Sell	25,289 -11,395	-31%	-$527K	0.09%	289
2016 Q3	$1.75M	Buy	36,684 +4,798	+15%	+$237K	0.13%	197
2016 Q2	$1.71M	Sell	31,886 -791	-2%	-$37.3K	0.13%	195
2016 Q1	$1.46M	Buy	32,677 +14,410	+79%	+$585K	0.1%	226
2015 Q4	$697K	Sell	18,267 -16,841	-48%	-$644K	0.05%	406
2015 Q3	$1.12M	Buy	35,108 +18,308	+109%	+$638K	0.08%	269
2015 Q2	$555K	Buy	+16,800	New	+$599K	0.03%	518

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Cadence Capital Management's ANIK Position: Q1 2017 in Review

Cadence Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2017, closing a stake of 25,289 shares — an estimated $1.24M sold.

Cadence Capital Management first reported a position in ANIK in Q2 2015 and held it in 7 quarters. The position peaked at $1.75M in Q3 2016. 156 funds tracked by Wall St. Rank hold ANIK as of Q1 2017.

Cadence Capital Management reported no remaining Anika Therapeutics position as of Q1 2017 after selling out during the quarter.
Cadence Capital Management sold 25,289 Anika Therapeutics shares in Q1 2017, an estimated $1.24M.
Cadence Capital Management first reported a position in Anika Therapeutics in Q2 2015 and held it in 7 quarters.
Cadence Capital Management's Anika Therapeutics position peaked at $1.75M in Q3 2016.
156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2017.

Based on Cadence Capital Management's 13F filing for Q1 2017, filed 11 May 2017.